NasdaqCM:VICL

Stock Analysis Report

Executive Summary

Vical Incorporated researches and develops biopharmaceutical products based on its DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases.

Snowflake

Fundamentals

Flawless balance sheet and overvalued.

Risks

  • Vical has significant price volatility in the past 3 months.
  • Vical is covered by less than 3 analysts.

Share Price & News

How has Vical's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

6.8%

NasdaqCM:VICL

1.5%

US Biotechs

0.9%

US Market


1 Year Return

-32.9%

NasdaqCM:VICL

-7.3%

US Biotechs

0.3%

US Market

VICL underperformed the Biotechs industry which returned -8% over the past year.

VICL underperformed the Market in United States of America which returned -0.5% over the past year.


Share holder returns

VICLIndustryMarket
7 Day6.8%1.5%0.9%
30 Day17.4%2.2%-1.9%
90 Day-25.6%3.5%1.6%
1 Year-32.9%-32.9%-6.5%-7.3%2.6%0.3%
3 Year-79.7%-79.7%8.9%5.2%41.0%31.8%
5 Year-93.4%-93.4%6.6%1.6%55.2%38.0%

Price Volatility Vs. Market

How volatile is Vical's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Vical undervalued based on future cash flows and its price relative to the stock market?

0.46x

Price to Book (PB) ratio


Intrinsic Value Based on Future Cash Flows

Unable to calculate intrinsic value for Vical to establish if it is available at moderate discount.

Unable to calculate intrinsic value for Vical to establish if it is available at substantial discount.


Price Based on Earnings

Vical is loss making, we can't compare its value to the US Biotechs industry average.

Vical is loss making, we can't compare the value of its earnings to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for Vical, we can't assess if its growth is good value.


Price Based on Value of Assets

Vical is good value based on assets compared to the US Biotechs industry average.


Next Steps

Future Growth

How is Vical expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

23.0%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Vical has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Vical performed over the past 5 years?

-0.07%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Vical does not make a profit and their year on year earnings growth rate was negative over the past 5 years.

Unable to compare Vical's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare Vical's 1-year growth to the US Biotechs industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if Vical has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if Vical has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if Vical improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is Vical's financial position?


Financial Position Analysis

Vical is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Vical has no long term commitments.


Debt to Equity History and Analysis

Vical has no debt.

Vical has not taken on any debt in the past 5 years.


Balance Sheet

Low level of unsold assets.

Vical has no debt, it does not need to be covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Vical has sufficient cash runway for 2.7 years based on current free cash flow.

Vical has sufficient cash runway for 2.3 years if free cash flow continues to grow at historical rates of 28.8% each year.


Next Steps

Dividend

What is Vical's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Vical's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Vical's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Vical has not reported any payouts.

Unable to verify if Vical's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Vical has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Vical's salary, the management and board of directors tenure and is there insider trading?

2.3yrs

Average management tenure


CEO

Vijay Samant (66yo)

18.8yrs

Tenure

US$1,029,354

Compensation

Mr. Vijay B. Samant has been the Chief Executive Officer and President of Vical Incorporation since November 2000. Mr. Samant joined Vical Inc. in November 2000. He served as Acting Chief Financial Officer ...


CEO Compensation Analysis

Vijay's remuneration is higher than average for companies of similar size in United States of America.

Vijay's compensation has been consistent with company performance over the past year, both up more than 20%.


Management Age and Tenure

2.3yrs

Average Tenure

58yo

Average Age

The tenure for the Vical management team is about average.


Board Age and Tenure

12.1yrs

Average Tenure

68yo

Average Age

The average tenure for the Vical board of directors is over 10 years, this suggests they are a seasoned and experienced board.


Insider Trading

No 3 month open market individual insider trading information.


Recent Insider Transactions

SellUS$1,930,70714 Jan 19
Armistice Capital LLC
EntityCompany
Shares2,190,500
Max PriceUS$0.88

Ownership Breakdown


Management Team

  • Vijay Samant (66yo)

    CEO, President & Director

    • Tenure: 18.8yrs
    • Compensation: US$1.03m
  • Tony Ramos (52yo)

    VP & CFO

    • Tenure: 2.3yrs
    • Compensation: US$433.47k
  • Larry Smith (58yo)

    Consultant

    • Tenure: 0.3yrs
    • Compensation: US$441.62k

Board Members

  • Gary Lyons (68yo)

    Director

    • Tenure: 22.4yrs
    • Compensation: US$65.70k
  • Richard Beleson (65yo)

    Director

    • Tenure: 6.3yrs
    • Compensation: US$55.70k
  • Vijay Samant (66yo)

    CEO, President & Director

    • Tenure: 18.8yrs
    • Compensation: US$1.03m
  • Greg Morrow (67yo)

    Director

    • Tenure: 6.8yrs
    • Compensation: US$70.70k
  • R. Douglas (84yo)

    Chairman of the Board

    • Tenure: 0.0yrs
    • Compensation: US$83.79k
  • Tom Shenk (72yo)

    Director

    • Tenure: 3.7yrs
    • Compensation: US$55.70k
  • Robert Merton (74yo)

    Director

    • Tenure: 17.4yrs
    • Compensation: US$73.70k

Company Information

Vical Incorporated's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Vical Incorporated
  • Ticker: VICL
  • Exchange: NasdaqCM
  • Founded: 1987
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$19.301m
  • Shares outstanding: 22.84m
  • Website: https://www.vical.com

Number of Employees


Location

  • Vical Incorporated
  • 10390 Pacific Center Court
  • San Diego
  • California
  • 92121
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
VICLNasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDMar 1993
VCC1DB (Deutsche Boerse AG)YesCommon StockDEEURMar 1993

Biography

Vical Incorporated researches and develops biopharmaceutical products based on its DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. The company was founde ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/08/19 23:43
End of Day Share Price2019/08/19 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.